NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
23 05 2019
Historique:
received: 03 12 2018
accepted: 21 02 2019
pubmed: 1 3 2019
medline: 24 12 2019
entrez: 1 3 2019
Statut: ppublish

Résumé

Neural cell adhesion molecule 1 (NCAM1; CD56) is expressed in up to 20% of acute myeloid leukemia (AML) patients. NCAM1 is widely used as a marker of minimal residual disease; however, the biological function of NCAM1 in AML remains elusive. In this study, we investigated the impact of NCAM1 expression on leukemogenesis, drug resistance, and its role as a biomarker to guide therapy. Beside t(8;21) leukemia, NCAM1 expression was found in most molecular AML subgroups at highly heterogeneous expression levels. Using complementary genetic strategies, we demonstrated an essential role of NCAM1 in the regulation of cell survival and stress resistance. Perturbation of NCAM1 induced cell death or differentiation and sensitized leukemic blasts toward genotoxic agents in vitro and in vivo. Furthermore, Ncam1 was highly expressed in leukemic progenitor cells in a murine leukemia model, and genetic depletion of

Identifiants

pubmed: 30814062
pii: S0006-4971(20)42538-8
doi: 10.1182/blood-2018-12-889725
doi:

Substances chimiques

Biomarkers, Tumor 0
CD56 Antigen 0
NCAM1 protein, human 0
Ncam1 protein, mouse 0
Neoplasm Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2305-2319

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Daniel Sasca (D)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Jakub Szybinski (J)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Andrea Schüler (A)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.

Viral Shah (V)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Jan Heidelberger (J)

Institute of Molecular Biology, Mainz, Germany.

Patricia S Haehnel (PS)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Anna Dolnik (A)

Hematology, Oncology and Tumor Immunology, Campus Virchow Hospital, Charité University Medicine, Berlin, Germany; and.

Oliver Kriege (O)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.

Eva-Marie Fehr (EM)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.

Wolf H Gebhardt (WH)

Institute of Molecular Biology, Mainz, Germany.

George Reid (G)

Institute of Molecular Biology, Mainz, Germany.

Claudia Scholl (C)

Division of Applied Functional Genomics, German Cancer Research Center/National Center for Tumor Diseases, Heidelberg, Germany.

Matthias Theobald (M)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Lars Bullinger (L)

Hematology, Oncology and Tumor Immunology, Campus Virchow Hospital, Charité University Medicine, Berlin, Germany; and.

Petra Beli (P)

Institute of Molecular Biology, Mainz, Germany.

Thomas Kindler (T)

Department of Hematology, Medical Oncology, and Pneumology, and.
Cancer Center, University Medical Center, Mainz, Germany.
German Consortia for Translational Cancer Research, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH